Lixia Diao
The University of Texas MD Anderson Cancer Center(US)The University of Texas MD Anderson Cancer Center(US)University of Waterloo(CA)Chongqing University(CN)Tianjin Medical University Cancer Institute and Hospital(CN)The University of Texas Health Science Center at Houston(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, RNA modifications and cancer, Phagocytosis and Immune Regulation, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance(2012)1,115 cited
- → Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression(2014)977 cited
- → Co-occurring Genomic Alterations Define Major Subsets of KRAS -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities(2015)897 cited
- → Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities(2021)886 cited
- → Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer(2019)860 cited
- → A pan-cancer proteomic perspective on The Cancer Genome Atlas